NYR Stock Overview
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nyrada Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.018 |
| Beta | 1.53 |
| 1 Month Change | -8.70% |
| 3 Month Change | 400.00% |
| 1 Year Change | -4.55% |
| 3 Year Change | -66.13% |
| 5 Year Change | n/a |
| Change since IPO | -55.32% |
Recent News & Updates
Shareholder Returns
| NYR | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -2.8% |
| 1Y | -4.5% | 31.9% | 4.0% |
Return vs Industry: NYR underperformed the Australian Pharmaceuticals industry which returned 31.9% over the past year.
Return vs Market: NYR underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| NYR volatility | |
|---|---|
| NYR Average Weekly Movement | 140.0% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: NYR's share price has been volatile over the past 3 months.
Volatility Over Time: NYR's weekly volatility has increased from 73% to 140% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | James Bonnar | www.nyrada.com |
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
Nyrada Inc. Fundamentals Summary
| NYR fundamental statistics | |
|---|---|
| Market cap | AU$18.84m |
| Earnings (TTM) | -AU$4.98m |
| Revenue (TTM) | AU$2.93m |
6.4x
P/S Ratio-3.8x
P/E RatioIs NYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYR income statement (TTM) | |
|---|---|
| Revenue | AU$2.93m |
| Cost of Revenue | AU$5.11m |
| Gross Profit | -AU$2.18m |
| Other Expenses | AU$2.80m |
| Earnings | -AU$4.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 17, 2024
| Earnings per share (EPS) | -0.028 |
| Gross Margin | -74.19% |
| Net Profit Margin | -169.82% |
| Debt/Equity Ratio | 0% |
How did NYR perform over the long term?
See historical performance and comparison